The identification of an osteoclastogenesis inhibitor through the inhibition of glyoxalase I

Osteoclasts, bone-resorptive multinucleated cells derived from hematopoietic stem cells, are associated with many bone-related diseases, such as osteoporosis. Osteoclast-targeting small-molecule inhibitors are valuable tools for studying osteoclast biology and for developing antiresorptive agents. Here, we have discovered that methyl-gerfelin (M-GFN), the methyl ester of the natural product gerfelin, suppresses osteoclastogenesis. By using M-GFN-immobilized beads, glyoxalase I (GLO1) was identified as an M-GFN-binding protein. GLO1 knockdown and treatment with an established GLO1 inhibitor in osteoclast progenitor cells interfered with osteoclast generation, suggesting that GLO1 activity is required for osteoclastogenesis. In cells, GLO1 plays a critical role in the detoxification of 2-oxoaldehydes, such as methylglyoxal. M-GFN inhibited the enzymatic activity of GLO1 in vitro and in situ. Furthermore, the cocrystal structure of the GLO1/M-GFN complex revealed the binding mode of M-GFN at the active site of GLO1. These results suggest that M-GFN targets GLO1, resulting in the inhibition of osteoclastogenesis.

[1]  H. Osada,et al.  Photo-cross-linked small-molecule affinity matrix for facilitating forward and reverse chemical genetics. , 2005, Angewandte Chemie.

[2]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[3]  Yong Zhou,et al.  LAFIRE: software for automating the refinement process of protein-structure analysis. , 2006, Acta crystallographica. Section D, Biological crystallography.

[4]  T A Jones,et al.  Crystal structure of human glyoxalase I—evidence for gene duplication and 3D domain swapping , 1997, The EMBO journal.

[5]  E G Kovaleva,et al.  Mechanism-based competitive inhibitors of glyoxalase I: intracellular delivery, in vitro antitumor activities, and stabilities in human serum and mouse serum. , 1999, Journal of medicinal chemistry.

[6]  M. Rogers.  New insights into the molecular mechanisms of action of bisphosphonates. , 2003, Current pharmaceutical design.

[7]  R. Holewinski,et al.  Glyoxalase I inhibitors in cancer chemotherapy. , 2003, Biochemical Society transactions.

[8]  S. Knapp,et al.  The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[9]  T. Tsuruo,et al.  Selective activation of apoptosis program by S-p-bromobenzylglutathione cyclopentyl diester in glyoxalase I-overexpressing human lung cancer cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  S. Yokoyama,et al.  Photo-cross-linked small-molecule microarrays as chemical genomic tools for dissecting protein-ligand interactions. , 2006, Chemistry, an Asian journal.

[11]  J. Woo,et al.  Compactin Suppresses Bone Resorption by Inhibiting the Fusion of Prefusion Osteoclasts and Disrupting the Actin Ring in Osteoclasts , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  Hiroshi Takayanagi,et al.  Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. , 2002, Developmental cell.

[13]  D. J. Creighton,et al.  Bivalent transition-state analogue inhibitors of human glyoxalase I. , 2003, Organic letters.

[14]  M. de Vernejoul,et al.  Cyclosporin-A in vitro decreases bone resorption, osteoclast formation, and the fusion of cells of the monocyte-macrophage lineage. , 1991, Endocrinology.

[15]  T. Usui,et al.  Iejimalides Show Anti-Osteoclast Activity via V-ATPase Inhibition , 2006, Bioscience, biotechnology, and biochemistry.

[16]  S. Sone,et al.  Reveromycin A Inhibits Osteolytic Bone Metastasis of Small-Cell Lung Cancer Cells, SBC-5, through an Antiosteoclastic Activity , 2005, Clinical Cancer Research.

[17]  Masanori Kato,et al.  Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Imoto,et al.  Gerfelin, a novel inhibitor of geranylgeranyl diphosphate synthase from Beauveria felina QN22047. II. Structural elucidation. , 2003, The Journal of antibiotics.

[19]  G. Wesolowski,et al.  Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[21]  M. Uesugi,et al.  Polyproline-rod approach to isolating protein targets of bioactive small molecules: isolation of a new target of indomethacin. , 2007, Journal of the American Chemical Society.

[22]  Sakae Tanaka,et al.  Wortmannin, a specific inhibitor of phosphatidylinositol‐3 kinase, blocks osteoclastic bone resorption , 1995, FEBS letters.

[23]  Paul J Thornalley,et al.  Antitumour activity of S-p-bromobenzylglutathione cyclopentyl diester in vitro and in vivo. Inhibition of glyoxalase I and induction of apoptosis. , 1996, Biochemical pharmacology.

[24]  A. McIntosh,et al.  Gene structure, intracellular localization, and functional roles of sterol carrier protein-2. , 2001, Progress in lipid research.

[25]  T. Terwilliger.  Electronic Reprint Biological Crystallography Map-likelihood Phasing Biological Crystallography Map-likelihood Phasing , 2022 .

[26]  A D Cameron,et al.  Reaction mechanism of glyoxalase I explored by an X-ray crystallographic analysis of the human enzyme in complex with a transition state analogue. , 1999, Biochemistry.

[27]  Kazuki Inamori,et al.  SPR imaging of photo-cross-linked small-molecule arrays on gold. , 2006, Analytical chemistry.

[28]  E. Jimi,et al.  Specific Inhibitors of Vacuolar H+‐ATPase Trigger Apoptotic Cell Death of Osteoclasts , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  S. Rahlfs,et al.  Characterization of the glyoxalases of the malarial parasite Plasmodium falciparum and comparison with their human counterparts , 2005, Biological chemistry.

[30]  S. Barnes,et al.  Variable effects of tyrosine kinase inhibitors on avian osteoclastic activity and reduction of bone loss in ovariectomized rats , 1996, Journal of cellular biochemistry.

[31]  D E McRee,et al.  XtalView/Xfit--A versatile program for manipulating atomic coordinates and electron density. , 1999, Journal of structural biology.

[32]  Paul J Thornalley.  Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. , 1998, Chemico-biological interactions.

[33]  M. Imoto,et al.  Gerfelin, a novel inhibitor of geranylgeranyl diphosphate synthase from Beauveria felina QN22047. I. Taxonomy, fermentation, isolation, and biological activities. , 2003, The Journal of antibiotics.

[34]  A. Vagin,et al.  MOLREP: an Automated Program for Molecular Replacement , 1997 .

[35]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[36]  T. Martin,et al.  Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. , 1999, Endocrine reviews.

[37]  Hiroyuki Osada,et al.  [Special Issue: Fact Databases and Freewares] RIKEN Natural Products Encyclopedia (RIKEN NPEdia),a Chemical Database of RIKEN Natural Products Depository (RIKEN NPDepo) , 2006 .

[38]  M. Kavarana,et al.  Pharmacokinetics and antitumor properties in tumor-bearing mice of an enediol analogue inhibitor of glyoxalase I , 2000, Cancer Chemotherapy and Pharmacology.

[39]  L. Hofbauer,et al.  Receptor activator of nuclear factor‐κB ligand and osteoprotegerin , 2001 .

[40]  H. Osada,et al.  Immobilization of natural products on glass slides by using a photoaffinity reaction and the detection of protein-small-molecule interactions. , 2003, Angewandte Chemie.

[41]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.